The short answer
KLOW is a co-lyophilised research blend of four peptides in one vial: KPV at 342.43 Da, GHK-Cu at 402.92 Da, BPC-157 at 1419.5 Da and TB-500 (full-length thymosin beta-4) at 4,963 Da, totalling 80mg. It is GLOW's three components plus KPV.
Key facts
- Components
- Four
- KPV
- 342.43 Da, CID 125672
- GHK-Cu
- 402.92 Da, CID 71587328
- TB-500 (thymosin beta-4)
- 4,963 Da, CID 16132341
- BPC-157
- 1419.5 Da, CID 9941957
- Total mass
- 80 mg
- Size range
- 342.43 to 4,963 Da, over fourteenfold
- Relationship to GLOW
- Same three plus KPV
What it is
The KLOW peptide blend is four peptides freeze-dried together in one vial. Three of them, GHK-Cu, BPC-157 and TB-500, make up the GLOW stack. KLOW adds KPV, the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, and raises the total from 70mg to 80mg.
What KPV brings
A different literature. The other three sit in collagen, repair and cell migration research; KPV's published work is anti-inflammatory, including murine colitis models and a targeted delivery study. Adding it widens the blend's research coverage rather than reinforcing what was already there.
Research material referenced
KLOW 80mg, third-party HPLC tested
The size range this creates
342.43 Da to 4,963 Da, a span of more than fourteenfold, the widest of any product in this catalogue. Four molecules of very different size, charge and solubility in one co-lyophilised cake. That has practical consequences for how the material dissolves and for what a single set of storage conditions has to accommodate.
An unremarked family connection
KPV descends from alpha-MSH. So does MT-2, which sits in a completely separate product category here, and the two take opposite halves of that hormone, KPV the anti-inflammatory C-terminus and MT-2 the receptor-binding core. Nothing in either product listing indicates they are related at all.
The figure that is still absent
80mg is a total across four components, and the split is not stated. With four components rather than three there are more unknowns, not fewer, and the same limitation applies with more force: no per-component molar calculation is possible.
Regulatory position
None of the four components holds a marketing authorisation from the MHRA, EMA or FDA, and neither does the blend. It is supplied for laboratory research only.
Frequently asked questions
What is in KLOW?
KPV at 342.43 Da, GHK-Cu at 402.92 Da, BPC-157 at 1419.5 Da and TB-500 (full-length thymosin beta-4) at 4,963 Da, totalling 80mg.
How does it differ from GLOW?
It is the same three components plus KPV, at 80mg rather than 70mg.
Is the per-component split stated?
No. With four components there are more unknowns than in a three-component blend, not fewer.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedGoldstein AL et al., Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med 2005 (PMID 16099219)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · Lys-Pro-Val (CID 125672)pubchem.ncbi.nlm.nih.gov
- PubChemPubChem · GHK-Cu copper complex (CID 71587328)pubchem.ncbi.nlm.nih.gov
- PubChemPubChem · BPC-157 (CID 9941957)pubchem.ncbi.nlm.nih.gov
- PubMedKannengiesser K et al., Melanocortin-derived tripeptide KPV in murine colitis. Inflamm Bowel Dis 2008 (PMID 18092346)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More KLOW (Blend) articles
- What You Can and Cannot Ask a Four-Component BlendA fixed ratio removes the ability to vary one component. Which experimental questions survive that, and which require separate vials.
- A Fourteenfold Size Range in One Vial342.43 Da to 1419.5 Da is the widest span in this catalogue. What that means for how the cake redissolves and what partial dissolution looks like.
- Storing Four Peptides Under One Set of ConditionsFour components, one vial, one storage condition. Why light protection is required and why no reducing agent or chelator is needed.
- Four Literatures, No Combination LiteratureEach component has published work of varying quality. The combination has none. What that distinction actually means for reading claims.
- Half of This Blend Is Small Enough to Share a RouteKPV is a demonstrated PepT1 substrate. GHK is also a tripeptide. Whether the two compete for the same carrier has never been asked, let alone answered.